UNLABELLED: CD8+ T-cell responses to hepatitis C virus (HCV) are important in generating a successful immune response and spontaneously clearing infection. Human leukocyte antigen (HLA) class I presents viral peptides to CD8+ T cells to permit detection of infected cells, and tapasin is an important component of the peptide loading complex for HLA class I. We sought to determine if tapasin polymorphisms affected the outcome of HCV infection. Patients with resolved or chronic HCV infection were genotyped for the known G/C coding polymorphism in exon 4 of the tapasin gene. In a European, but not a US, Caucasian population, the tapasin G allele was significantly associated with the outcome of HCV infection, being found in 82.5% of resolvers versus 71.3% of persistently infected individuals (P = 0.02, odds ratio [OR] = 1.90 95% confidence interval [CI] = 1.11-3.23). This was more marked at the HLA-B locus at which heterozygosity of both tapasin and HLA-B was protective (P < 0.03). Individuals with an HLA-B allele with an aspartate at residue 114 and the tapasin G allele were more likely to spontaneously resolve HCV infection (P < 0.00003, OR = 3.2 95% CI = 1.6-6.6). Additionally, individuals with chronic HCV and the combination of an HLA-B allele with an aspartate at residue 114 and the tapasin G allele also had stronger CD8+ T-cell responses (P = 0.02, OR = 2.58, 95% CI-1.05-6.5). CONCLUSION: Tapasin alleles contribute to the outcome of HCV infection by synergizing with polymorphisms at HLA-B in a population-specific manner. This polymorphism may be relevant for peptide vaccination strategies against HCV infection.
UNLABELLED: CD8+ T-cell responses to hepatitis C virus (HCV) are important in generating a successful immune response and spontaneously clearing infection. Human leukocyte antigen (HLA) class I presents viral peptides to CD8+ T cells to permit detection of infected cells, and tapasin is an important component of the peptide loading complex for HLA class I. We sought to determine if tapasin polymorphisms affected the outcome of HCV infection. Patients with resolved or chronic HCV infection were genotyped for the known G/C coding polymorphism in exon 4 of the tapasin gene. In a European, but not a US, Caucasian population, the tapasin G allele was significantly associated with the outcome of HCV infection, being found in 82.5% of resolvers versus 71.3% of persistently infected individuals (P = 0.02, odds ratio [OR] = 1.90 95% confidence interval [CI] = 1.11-3.23). This was more marked at the HLA-B locus at which heterozygosity of both tapasin and HLA-B was protective (P < 0.03). Individuals with an HLA-B allele with an aspartate at residue 114 and the tapasin G allele were more likely to spontaneously resolve HCV infection (P < 0.00003, OR = 3.2 95% CI = 1.6-6.6). Additionally, individuals with chronic HCV and the combination of an HLA-B allele with an aspartate at residue 114 and the tapasin G allele also had stronger CD8+ T-cell responses (P = 0.02, OR = 2.58, 95% CI-1.05-6.5). CONCLUSION:Tapasin alleles contribute to the outcome of HCV infection by synergizing with polymorphisms at HLA-B in a population-specific manner. This polymorphism may be relevant for peptide vaccination strategies against HCV infection.
Authors: Tariq Ahmad; Matt Neville; Sara E Marshall; Alessandro Armuzzi; Kim Mulcahy-Hawes; Jonathan Crawshaw; Hiroe Sato; Khoon-Lin Ling; Martin Barnardo; Sue Goldthorpe; Robert Walton; Mike Bunce; Derek P Jewell; Ken I Welsh Journal: Hum Mol Genet Date: 2003-03-15 Impact factor: 6.150
Authors: Chloe L Thio; Xiaojiang Gao; James J Goedert; David Vlahov; Kenrad E Nelson; Margaret W Hilgartner; Stephen J O'Brien; Peter Karacki; Jacquie Astemborski; Mary Carrington; David L Thomas Journal: J Virol Date: 2002-05 Impact factor: 5.103
Authors: Salim I Khakoo; Chloe L Thio; Maureen P Martin; Collin R Brooks; Xiaojiang Gao; Jacquie Astemborski; Jie Cheng; James J Goedert; David Vlahov; Margaret Hilgartner; Steven Cox; Ann-Margeret Little; Graeme J Alexander; Matthew E Cramp; Stephen J O'Brien; William M C Rosenberg; David L Thomas; Mary Carrington Journal: Science Date: 2004-08-06 Impact factor: 47.728
Authors: Susan M McKiernan; Richard Hagan; Michael Curry; George S A McDonald; Alan Kelly; Niamh Nolan; Anne Walsh; John Hegarty; Emer Lawlor; Dermot Kelleher Journal: Hepatology Date: 2004-07 Impact factor: 17.425
Authors: Jason Grebely; Gregory J Dore; Arthur Y Kim; Andrew Lloyd; Naglaa H Shoukry; Maria Prins; Kimberly Page Journal: Hepatology Date: 2014-05-27 Impact factor: 17.425
Authors: Jiansheng Jiang; Daniel K Taylor; Ellen J Kim; Lisa F Boyd; Javeed Ahmad; Michael G Mage; Hau V Truong; Claire H Woodward; Nikolaos G Sgourakis; Peter Cresswell; David H Margulies; Kannan Natarajan Journal: Nat Commun Date: 2022-09-17 Impact factor: 17.694
Authors: T J Hydes; B Moesker; J A Traherne; S Ashraf; G J Alexander; B D Dimitrov; C H Woelk; J Trowsdale; S I Khakoo Journal: Tissue Antigens Date: 2015-10
Authors: K M Jamil; T J Hydes; K S Cheent; S A Cassidy; J A Traherne; J Jayaraman; J Trowsdale; G J Alexander; A-M Little; H McFarlane; M A Heneghan; M A Purbhoo; S I Khakoo Journal: Gut Date: 2016-02-17 Impact factor: 23.059